Camp4 Therapeutics (CAMP) EBIT Margin (2023 - 2026)

Camp4 Therapeutics has disclosed EBIT Margin across 4 years of filings, most recently posting 1010.12% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 1010.12%, up 51668.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1335.18% (up 219542.0% YoY), and the FY2025 annual result was 1502.43%, up 663990.0% from the prior year.
• EBIT Margin came in at 1010.12% for Q1 2026 at Camp4 Therapeutics, up from 3671.26% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 870.27% in Q2 2025 to a low of 3671.26% in Q4 2025.
• The 4-year median for EBIT Margin is 1717.11% (2025), against an average of 2067.6%.
• Across the five-year window, EBIT Margin tumbled 151881 bps in 2025 and surged 51668 bps in 2026, its largest moves.
• Camp4 Therapeutics' EBIT Margin stood at 3525.14% in 2023, then jumped by 39 bps to 2152.45% in 2024, then tumbled by 71 bps to 3671.26% in 2025, then surged by 72 bps to 1010.12% in 2026.
• The last three EBIT Margin figures came in at 1010.12% (Q1 2026), 3671.26% (Q4 2025), and 1717.11% (Q3 2025), per Business Quant data.